NCT04937881View on ClinicalTrials.gov

PK of TAF and TDF for PrEP in Pregnant and Postpartum Women

PHASE3CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 13, 2022

Primary Completion Date

April 17, 2023

Study Completion Date

September 1, 2023

Conditions
Hiv
Interventions
DRUG

Tenofovir alafenamide

Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF)

DRUG

Tenofovir Disoproxil Fumarate

Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF)

Trial Locations (1)

Unknown

Gugulethu Midwife Obstetric Unit, Cape Town

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

University of Cape Town

OTHER

collaborator

Desmond Tutu HIV Foundation

OTHER

collaborator

Gilead Sciences

INDUSTRY

lead

University of California, Los Angeles

OTHER